Monday, September 08, 2025

 

Nicotine pouches may offer path to reduced tobacco harm, Rutgers study finds



In first national estimate of daily nicotine pouch use in the U.S., public health researchers find reason for optimism




Rutgers University




As lawmakers and public health experts debate the safety of nicotine pouches, researchers from Rutgers Health found that for now, most adults that use these products also have a history of tobacco use and may be choosing these products as a possible step toward reducing or quitting more dangerous forms of nicotine delivery.

The findings – believed to be the first national estimates of daily nicotine pouch use in the U.S. – were published in JAMA Network Open.

Faced with declining cigarette sales, tobacco manufacturers in the U.S. are turning to tobacco-free nicotine pouches, such as Velo and Zyn, which are among the few segments of the industry that’s growing.

In January 2025, the U.S. Food and Drug Administration authorized the marketing of ZYN, the first nicotine pouch to receive such authorization. Importantly, pouches cannot be marketed as smoking cessation aids – such as patches, gums and lozenges approved for therapeutic use – even if some people appear to be turning to them for that reason.

Against this backdrop, Cristine D. Delnevo, director of the Rutgers Institute for Nicotine and Tobacco Studies, set out to assess how widely nicotine pouches are being used among U.S. adults, and to establish a baseline for monitoring future changes in user habits.

By analyzing data from the U.S. Census Bureau’s 2022-2023 Tobacco Use Supplement, which surveyed more than 110,000 adults across the country on their use of nicotine pouches and traditional tobacco products, the researchers painted a picture of nicotine pouch uptake in the U.S. They examined quitting behavior of other tobacco products before and after 2019, when the product became widely available nationally.

They found that overall, the percentage of adults using the product remains low – just 2.5% non-Hispanic white men were the most likely to have used the product. Use among tobacco-naïve adults – those who had never used tobacco products – was virtually non-existent.

Most compelling, Delnevo said, the highest prevalence of current and daily nicotine pouch use was among adults with a history of tobacco use who had recently quit, suggesting that nicotine pouches may have played a role in their cessation.

“Our results suggest that adults may be using nicotine pouches for harm reduction given that use is highest among those that have recently quit another tobacco product or e-cigarettes,” said Delnevo, who is also a distinguished professor at the Rutgers School of Public Health.

But questions remain. Researchers continue to study the long-term health effects of oral nicotine pouches. While nicotine itself does not cause cancer, nicotine is highly addictive and its use can impact cardiovascular health, such as by increasing blood pressure, among other concerns.

Evidence also suggests that the popularity of pouches may be increasing among young people, albeit slowly. The Centers for Disease Control and Prevention’s 2024 National Youth Tobacco Survey found that 1.8% of U.S. middle and high school students reported using nicotine pouches, up from 1.1% in 2022.

That trend has added urgency to warnings from Delnevo and her colleagues, who in a previous JAMA commentary, urged the FDA to ensure the oral nicotine marketplace did not proliferate as uncontrollably as e-cigarettes.

“We should always keep a watchful eye on youth tobacco-use behaviors, including use of multiple products, substitution with other products or alternative methods of finding and using flavored tobacco and nicotine products,” she said.

Yet, when used by established tobacco users, pouches may offer a health benefit, she added.

“People who have never used tobacco products should not suddenly be using nicotine pouches,” she said. “But for people who smoke or use other nicotine products and don’t want to stop using nicotine, switching completely from the more harmful product and moving down the risk continuum with nicotine pouches is a likely good for public health.”

Mary Hrywna, an associate professor in the Department of Health Behavior, Society and Policy at the Rutgers School of Public Health, and a study co-author, agreed.

“As nicotine pouches gain increased attention in the U.S., many agree that we need to better understand who is using these products and how,” Hrywna said. “This study offers a snapshot of use patterns that is informative and, at least for now, somewhat reassuring.”

 

Young children are not the main drivers of language change



Adolescents and young adults being the agents of change



Max Planck Institute for Psycholinguistics






Theoretical study by Limor Raviv, Damian Blasi and Vera Kempe, argues that children are not likely to be the main force behind linguistic innovation.


For more than a century, scholars have repeated a powerful idea: that the mistakes children make when learning to speak are the seeds of language change. From 19th-century linguist Henry Sweet’s famous claim that “if languages were learnt perfectly by the children of each generation, then languages would not change,” to contemporary studies, the notion that children drive language evolution has been pervasive in linguistics, psychology, and even popular understanding.

The new theoretical paper Children are not the main agents of language change argues that this popular belief is unfounded: language change is not the result of children’s acquisition errors. Instead, the real engine of change is everyday language use among older speakers, with adolescents and young adults being the more likely agents of change.  

The role of everyday language use

“We show that the mistakes made my small children acquiring their first language are not likely to persist and to spread to the wider community. language change is more likely to emerge from the ways adults and adolescents adapt, innovate, and interact in real communicative settings,” the authors explain. “children recover from most of their cute mistakes as they grow older, and anyway lack the social stance required for us to copy them”.

The paper reviews classic arguments for the child-driven view and finds little evidence that early learning mistakes spread through communities. Instead, it highlights the social authority, creative expression, and interactional flexibility of adolescents and adults as  potential factors that enable new linguistic forms to take hold and persist.


Reframing the debate

Beyond reframing the academic debate, the authors emphasize the importance of correcting a misconception that is also widespread in public discussions about language. They hope the paper will encourage researchers to scrutinize the empirical evidence underlying their claims - even when those claims have been repeated for decades.

“We see the main value of our work in encouraging a better allocation of research resources,” the authors note. “Rather than focusing narrowly on acquisition errors in children, we should explore the broader social, historical, and interactional processes that underpin language emergence and change. This approach promises better explanations for how and why languages evolve.”

By de-emphasizing the role of child learners and foregrounding the role of language use by adolescents and adults, the study calls for a shift in how linguistic change is studied and taught. It urges the field to look beyond universal cognitive biases and give greater attention to the social contexts in which people use language.
 

ASBESTOS

Clinical study deepens understanding of mesothelioma and opens the door to potential treatment options





Georgetown University Medical Center





WASHINGTON – People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.  

Mesothelioma is a rare cancer that affects the tissue that lines many organs of the body. Approximately 30,000 cases are diagnosed every year worldwide, most of them in the pleura, or lining of the lungs. It occurs most often in people who have been exposed to asbestos.

“Mesothelioma is a difficult tumor to treat,” said the study’s lead author Joshua Reuss, MD, a thoracic medical oncologist with Georgetown’s Lombardi Comprehensive Cancer Center. “Our study demonstrated the feasibility and safety of using immunotherapy before surgery for patients who have tumors that can potentially be removed surgically.

“Immunotherapy is making substantial contributions to extending the lives of patients with lung cancer and many other solid tumors. This is an important step in identifying mesothelioma patients who could benefit from immunotherapy in the perioperative period, meaning right before or after their surgery and in choosing patients who are actually candidates for that surgery,” said Reuss, who is also an attending physician at MedStar Georgetown University Hospital.

Reuss designed the clinical trial during fellowship training at the Johns Hopkins Kimmel Cancer Center, the primary site where the study was conducted. He presented the results of the phase II study, Neoadjuvant Nivolumab or Nivolumab plus Ipililumab in Resectable Diffuse Pleural Mesothelioma, at the 2025 World Conference on Lung Cancer in Barcelona, Spain on September 8 and is lead author of the study published concurrently in the journal Nature Medicine (DOI 10.1038/s41591-025-03958-3).

 Phase II clinical trials are designed to assess whether it is possible to deliver innovative treatments to specific patient populations, and whether the potential benefits of the therapy outweigh any adverse effects that patients experience.

“When looking at patient outcomes to date, the issue of whether any mesothelioma is truly resectable is controversial,” said Reuss. “Several major studies have not shown improvement in survival when surgery is incorporated into systemic therapy for mesothelioma. This study incorporates immunotherapy into the treatment of patients who might benefit from surgery. 

“Since they occur in the tissue that lines the lungs, mesotheliomas don’t grow and spread like other cancers.” Reuss said. “They don’t typically form solid masses or nodules. These tumors are more fluid, or diffuse throughout the lining of the lung. That makes it more difficult to use our usual methods to determine how extensive a tumor is or to measure whether a treatment is effective by standard imaging assessments.”

In this study, the clinical team worked closely with scientists in the laboratory to test a novel approach studying circulating tumor DNA (ctDNA) in their patient’s blood. Tumors frequently shed cancer DNA into the blood stream. Oncologists can test the blood to detect the presence of this ctDNA, but their role in clinical decision-making is an evolving area of interest. This is particularly challenging in mesothelioma, a tumor type that has a low number of cancer mutations that can be detected by traditional ctDNA techniques.

“Imaging doesn’t always capture what’s happening with mesothelioma, especially during treatment,” said the study’s senior author, Valsamo Anagnostou, MD, PhD, the Alex Grass professor of oncology and co-director of the upper aerodigestive cancers program at Johns Hopkins. “By using an ultra-sensitive genome-wide ctDNA sequencing method, we were able to detect microscopic signs of cancer that imaging missed and predict which patients were most likely to benefit from treatment or experience relapse.”

“This approach may give us a baseline to monitor the efficacy of that treatment,” Reuss said. “If the ctDNA decreases or disappears, it is a good indication that the therapy is working, If not, it indicates a change in therapy may be warranted.” Reuss added that further validation of this methodology is required before it can routinely be incorporated into clinical practice.

“These analyses contribute to our understanding of which patients with mesothelioma may be candidates for surgery,” Reuss said. “Up until now, ctDNA assessments have not been part of the clinical landscape in the management of diffuse pleural mesothelioma, but our analyses suggest this may be nearing a change in the future.”

Phase II clinical trials are not designed to measure the clinical efficacy of treatment options but  both arms of this trial showed improvements in the time from treatment to when the tumors began to grow again and overall length of survival.

Reuss cautions against drawing conclusions about that data, but notes that the results do provide positive signals about the potential value of neoadjuvant immunotherapy for mesothelioma patients with tumors that can be surgically removed and point the way to future studies.

“This is a small study,” he said, “and it does not tell us whether neoadjuvant immunotherapy will improve outcomes for these patients, but it does open windows of opportunity. We need to take what we learned and do further studies, dig deeper so that we can develop better therapies for patients with mesothelioma.” 

###

 

The study was conducted across multiple academic cancer centers. The trial was sponsored by Bristol Myers Squibb. The research was supported in part by the Department of Defense Congressionally Directed Medical Research Programs grant CA190755, the Johns Hopkins Kimmel Cancer Center NCI Support Grant NCI CCSG P30 CA006973, the US Food and Drug Administration grant U01FD005942-FDA, National Institutes of Health grant CA1211113, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center Grant UG1CA233259, the Robyn Adler Fellowship Award, the Commonwealth Foundation, the Mark Foundation for Cancer Research, and the Florence Lomax Eley Fund.

Reuss reports receives research funding through Georgetown University from Genentech/Roche, Verastem, Nuvalent, Arcus,  Revolution Medicines, Regeneron, Amgen, DualityBio, and AstraZeneca, and serves in a consultant/advisory role for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Seagen, Gilead, Janssen, Novocure, Regeneron, Summit Therapeutics, Pfizer, Lilly, Natera, Merck, EMD Serono, Roche Diagnostics, and OncoHost. Anagnostou reports receiving research funding from Astra Zeneca and Personal Genome Diagnostics, Bristol-Myers Squibb, and Delfi Diagnostics, is an advisor to Astra Zeneca and Neogenomics and receives honoraria from Foundation Medicine, Guardant Health, Roche and Personal Genome Diagnostics. Other author disclosures are included in the manuscript.

Additional authors include Paul K. Lee, Reza J. Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J. Battafarano, Russell K. Hales, Joseph Friedberg, Boris Sepesi, Julie S. Deutsch, Tricia Cottrell, Janis Taube, Peter B. Illei, Kellie N. Smith, Drew M. Pardoll, Anne S. Tsao, Julie R. Brahmer, and Patrick M. Forde.

 

 

 

 

New and simple detection method for nanoplastics.

Researchers at the University of Stuttgart have developed an “optical sieve” for detecting tiny nanoplastic particles. It works like a test strip and is intended to serve as a new analysis tool in environmental and health research.

Peer-Reviewed Publication

Universitaet Stuttgart

Nanoplastic particles made visible: the newly developed test strip from the University of Stuttgart allows dangerous nanoplastic particles to be detected under a light microscope. 

image: 

Nanoplastic particles made visible: the newly developed test strip from the University of Stuttgart allows dangerous nanoplastic particles to be detected under a light microscope.

view more 

Credit: University of Stuttgart / 4th Physics Institute

A joint team from the University of Stuttgart in Germany and the University of Melbourne in Australia has developed a new method for the straightforward analysis of tiny nanoplastic particles in environmental samples. One needs only an ordinary optical microscope and a newly developed test strip—the optical sieve. The research results have now been published in “Nature Photonics” (doi: 10.1038/s41566-025-01733-x).

“The test strip can serve as a simple analysis tool in environmental and health research,” explains Prof. Harald Giessen, Head of the 4th Physics Institute of the University of Stuttgart. “In the near future, we will be working toward analyzing nanoplastic concentrations directly on site. But our new method could also be used to test blood or tissue for nanoplastic particles.”

Nanoplastics as a danger to humans and the environment

Plastic waste is one of the central and acute global problems of the 21st century. It not only pollutes oceans, rivers, and beaches but has also been detected in living organisms in the form of microplastics. Until now, environmental scientists have focused their attention on larger plastic residues. However, it has been known for some time that an even greater danger may be on the horizon: nanoplastic particles. These tiny particles are much smaller than a human hair and are created through the breakdown of larger plastic particles. They cannot be seen with the naked eye. These particles in the sub-micrometer range can also easily cross organic barriers such as the skin or the blood-brain barrier.

Color changes make tiny particles visible

Because of the small particle size, their detection poses a particular challenge. As a result, there are not only gaps in our understanding of how particles affect organisms but also a lack of rapid and reliable detection methods. In collaboration with a research group from Melbourne in Australia, researchers at the University of Stuttgart have now developed a novel method that can quickly and affordably detect such small particles. Color changes on a special test strip make nanoplastics visible in an optical microscope and allow researchers to count the number of particles and determine their size. “Compared with conventional and widely used methods such as scanning electron microscopy, the new method is considerably less expensive, does not require trained personnel to operate, and reduces the time required for detailed analysis,” explains Dr. Mario Hentschel, Head of the Microstructure Laboratory at the 4th Physics Institute.

Optical sieve instead of expensive electron microscope

The “optical sieve” uses resonance effects in small holes to make the nanoplastic particles visible. A study on optical effects in such holes was first published by the research group at the University of Stuttgart in 2023. The process is based on tiny depressions, known as Mie voids, which are edged into a semiconductor substrate. Depending on their diameter and depth, the holes interact characteristically with the incident light. This results in a bright color reflection that can be seen in an optical microscope. If a particle falls into one of the indentations, its color changes noticeably. One can therefore infer from the changing color whether a particle is present in the void.

“The test strip works like a classic sieve,” explains Dominik Ludescher, PhD student and first author of the publication in “Nature Photonics”. Particles ranging from 0.2 to 1 µm can thus be examined without difficulty. “The particles are filtered out of the liquid using the sieve in which the size and depth of the holes can be adapted to the nanoplastic particles, and subsequently by the resulting color change can be detected. This allows us to determine whether the voids are filled or empty.”

Number, size, and size distribution of particles can be determined

The novel detection method used can do even more. If the sieve is provided with voids of different sizes, only one particle of a suitable size will collect in each hole. “If a particle is too large, it won’t fit into the void and will be simply flushed away during the cleaning process,” says Ludescher. “If a particle is too small, it will adhere poorly to the well and will be washed away during cleaning.” In this way, the test strips can be adapted so that the size and number of particles in each individual hole can be determined from the reflected color.

Synthesized environmental samples examined

For their measurements, the researchers used spherical particles of various diameters. These are available in aequous solutions with specific nanoparticle. Because real samples from bodies of water with known nanoparticle concentrations are not yet available, the team produced a suitable sample themselves. The researchers used a water sample from a lake that contained a mixture of sand and other organic components and added spherical particles in known quantities. The concentration of plastic particles was 150 µg/ml. The number and size distribution of the nanoplastic particles was also be determined for this sample using the “optical sieve”.

Can be used like a test strip

“In the long term, the optical sieve will be used as a simple analysis tool in environmental and health research. The technology could serve as a mobile test strip that would provide information on the content of nanoplastics in water or soil directly on site,” explains Hentschel. The team is now planning experiments with nanoplastic particles that are not spherical. The researchers also plan to investigate whether the process can be used to distinguish between particles of different plastics. They are also particularly interested in collaborating with research groups that have specific expertise in processing real samples from bodies of water.

The optical sieve nanoplastic particles fall into holes of the appropriate size in the test strip. The color of the holes changes. The new color provides information about the size and number of particles.

Credit

University of Stuttgart / 4th Physics Institute